Open an account

ICON

ICLR · NASDAQ

$174.19+$6.05 (+3.60%)TodayMarket closed ·
Prev close $168.14

About ICLR

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. The company offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The firm's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. The company also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees
39,800
Headquarters
DUBLIN, Dublin
Listed
May 15, 1998
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
iconplc.com

ICLR key statistics

Market cap
13.44B
Price-earnings ratio
175.15
Dividend yield
—
Average volume
917.80K
Volume
935.60K
Open price
$169.26
High today
$176.73
Low today
$168.64
52 Week high
$203.91
52 Week low
$66.57

ICON (ICLR) at a glance

As of Oct 20, 2026, ICON (ICLR) shares are priced at $174.19, giving the company a market cap of 13.44B and a price-to-earnings ratio of 175.15.

Today the stock has traded between $168.64 and $176.73. The current price is 3.3% above the day's low and 1.4% below its high.

Volume so far is 935.60K shares, in line with the average of 917.80K shares a day.

Over the past year ICON has ranged from $66.57 to $203.91, and now sits 78% of the way up that range.

ICON met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported $2.56 per share against an estimate of $2.57.

The average analyst price target is $194.14, 11.5% above the current price, from 15 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

53%of 15 analyst ratings say Buy
  • Buy53.3%
  • Hold40.0%
  • Sell6.7%
Price target · 19 analystsAvg $194.14
Low
$161.60
Now
$174.19
High
$231.00

ICLR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 0.8% on average.

  1. Q3 FY24: reported $3.35 per share against an estimate of $3.91
  2. Q4 FY24: reported $3.43 per share against an estimate of $3.47
  3. Q1 FY25: reported $3.19 per share against an estimate of $3.18
  4. Q2 FY25: reported $3.26 per share against an estimate of $3.27
  5. Q3 FY25: reported $3.31 per share against an estimate of $3.35
  6. Q4 FY25: reported $2.52 per share against an estimate of $3.18
  7. Q1 FY26: reported $2.50 per share against an estimate of $2.47
  8. Q2 FY26: reported $2.56 per share against an estimate of $2.57

ICLR news

  • Press releaseBusiness Wire

    ICON Schedules Third Quarter 2026 Earnings Conference Call

  • Press releaseBusiness Wire

    ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability

  • Press releaseBusiness Wire

    ICON Announces Pricing of USD 2.15 Billion Notes

  • Press releaseBusiness Wire

    ICON Announces Private Offering of Notes

  • Press releaseBusiness Wire

    ICON Announces Results of Annual General Meeting

  • Press releaseBusiness Wire

    ICON Reports Second Quarter 2026 Results

  • Press releaseBusiness Wire

    ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

  • Press releaseBusiness Wire

    ICON Schedules Second Quarter 2026 Earnings Conference Call

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.